You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 17, 2024

Claims for Patent: 8,545,843

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,545,843

Title:	Treatment of vasculitis
Abstract:	The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
Inventor(s):	Curd; John G. (Hillsborough, CA), Grillo-Lopez; Antonio J. (San Diego, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA) Biogen Idec Inc. (Cambride, MA)
Application Number:	12/886,171
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,545,843
Patent Claims:	1. A method of treating vasculitis in a human who does not have rheumatoid arthritis or cancer comprising administering to the human a therapeutically effective amount of rituximab, wherein the administration of the rituximab consists of intravenous administration. 2. A method of treating vasculitis in a human who does not have rheumatoid arthritis or cancer comprising: (a) administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab; and (b) administering to the human glucocorticosteroid. 3. The method of claim 2 wherein the glucocorticosteroid is prednisone, methylprednisolone, or dexamethasone. 4. A method of treating vasculitis in a human who does not have rheumatoid arthritis or cancer comprising: (a) administering to the human more than one intravenous dose of a therapeutically effective amount of an antibody that binds to the CD20 antigen on human B lymphocytes; and (b) administering to the human glucocorticosteroid; wherein the CD20 antibody administration consists of intravenous administration of the CD20 antibody, and the CD20 antibody is rituximab. 5. The method of claim 4 wherein the glucocorticosteroid is prednisone, methylprednisolone, or dexamethasone. 6. A method of treating vasculitis in a human who does not have rheumatoid arthritis or cancer comprising: (a) administering to the human more than one intravenous dose of a therapeutically effective amount of an antibody that binds to the CD20 antigen on human B lymphocytes; and (b) administering to the human glucocorticosteroid; wherein the therapeutically effective amount of the CD20 antibody is administered intravenously, and the CD20 antibody is rituximab. 7. The method of claim 6 wherein the glucocorticosteroid is prednisone, methylprednisolone, or dexamethasone. 8. The method of claim 1 further comprising administering glucocorticosteroid to the human. 9. The method of claim 8 wherein the glucocorticosteroid is prednisone, methylprednisolone, or dexamethasone. 10. A method of treating vasculitis in a human who does not have rheumatoid arthritis or cancer comprising administering to the human rituximab in an amount effective to deplete B-cells in the human, wherein the administration of the rituximab consists of intravenous administration. 11. The method of claim 10 further comprising administering glucocorticosteroid to the human. 12. The method of claim 11 wherein the glucocorticosteroid is prednisone, methylprednisolone, or dexamethasone.

Details for Patent 8,545,843

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2019-05-07
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2019-05-07
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	⤷ Try a Trial	2019-05-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.